Drug Trial Radar · NCT05994534
PK and PD Study of NPI-001 and Cysteamine Bitartrate
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Oct 29, 2023
Primary completion
May 26, 2026
Study completion May 26, 2026
Sponsor
- Lead sponsor
- Nacuity Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 16, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 10 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Safety, pharmacokinetics, and pharmacodynamics of NPI-001 oral solution in cystinosis patients compared with cysteamine.
Conditions
- Cystinosis
Interventions
Cysteamine BitartrateDrug
Single dose, tablets at current therapeutic dose
N-Acetylcysteine AmideDrug
Single dose, oral solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Concentration of Cystine Levels Over TimeTime frame: 1 day
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Children's Hospital at Westmead
Westmead, New South Wales, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.